Primary resistance to first- and second-generation ALK inhibitors in a non-small cell lung cancer patient with coexisting ALK rearrangement and an ALK F1174L-cis-S1189C de novo mutation: A case report

• Main Authors: Jiuzhou Zhao (Author), Xiang Li (Author), Ruizhe Fan (Author), Yaping Qin (Author), Zhizhong Wang (Author), Bo Wang (Author), Shaomei Li (Author), Jianfeng Fan (Author), Xinxin Wu (Author), Hongxia Liu (Author), Yuping Guan (Author), Yinfeng Liang (Author), Xiao Zhang (Author), Yongjun Guo (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The effectiveness of the tyrosine kinase inhibitor ALK (TKI) for non-small cell lung cancer has been confirmed. However, resistance to ALK-TKIs seems inevitable. Mutations in the ALK kinase domain have been reported as an important mechanism of acquired resistance to ALK therapy. However, patients w...